Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/19/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Thomas Hecht

Wrong Dr. Thomas Hecht?

Chairman

Affimed Therapeutics AG
1 Orchard Place Nottingham Business Park
Nottingham , Nottinghamshire NG8 6PX
United Kingdom

Company Description: Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • MD
  • degree , Economics
80 Total References
Web References
Affimed Therapeutics
www.affimed.com, 19 Jan 2015 [cached]
Thomas Hecht, M.D. Chairman
Thomas Hecht, MD, is chairman of Affimed's Supervisory Board since 2007 and Head of HHC consulting in Kuessnacht, Switzerland. He was previously Vice President Marketing at Amgen Europe, Lucerne, Switzerland. A seasoned manager and industry professional, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany. Today, he provides services to the pharmaceutical industry in clinical development/ marketing and licensing strategies through HHC, a biopharmaceutical consulting company founded in 2002. He also serves as Chairman of the Boards of Cell Medica Ltd., Delenex AG and of the supervisory council of SuppreMol GmbH and as Member of the Board of Humabs BioMed AG. In 2009, with the acquisition by Alcon, he stepped down from the Chairmanship of ESBATech AG.
Thomas ...
www.telormedix.com, 16 Jan 2010 [cached]
Thomas Hecht
...
Thomas Hecht MD
Chairman of the Board
Dr. Hecht has extensive experience in clinical development and has served on the Board of Directors for several biotech companies including Cytos, ESBAtech, Affimed and Supremol. In addition, Dr. Hecht has held the position of VP Marketing at the European division of Amgen.
Board of directors - Cell Medica
www.cellmedica.co.uk, 9 Jan 2015 [cached]
Thomas Hecht Chairman
Thomas is an experienced biotechnology professional with a clinical background in haematology and internal medicine. He was a member of the team which helped build Amgen's European operations where he held various executive positions including Vice President - Marketing for Hematology and Oncology. ( MD, University of Freiburg).
Cell Medica announces the appointment of Dr. Thomas Hecht as Non-Executive Director
www.cellmedica.co.uk, 13 Oct 2010 [cached]
Cell Medica announces the appointment of Dr. Thomas Hecht as Non-Executive Director Cell Medica announces the appointment of Dr. Thomas Hecht as Non-Executive Director
...
Cell Medica announces the appointment of Dr. Thomas Hecht as Non-Executive Director Published: Oct. 13, 2010, midnight in Press releases
The Board of Cell Medica is pleased to announce the appointment of Dr. Thomas Hecht as a non-executive director. Cell Medica is a cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer.
London, UK - 13 October 2010: The Board of Cell Medica is pleased to announce the appointment of Dr. Thomas Hecht as a non-executive director. Cell Medica is a cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer.
Thomas brings a unique mix of clinical, industrial and early-stage life sciences company experience to the Board of Cell Medica. His clinical background in haematology/oncology and internal medicine fits well with Cell Medica's Cytovir immune reconstitution therapy aimed at treating infections in bone marrow transplant patients, and also the Company's pipeline products under development for lymphoma and leukaemia applications. With his experience as part of the team which built the European operations of Amgen, Thomas will help guide the launch of Cell Medica's pan-European marketing strategy for Cytovir.
Nigel Burns, Chairman of Cell Medica, said, "In view of his professional experience and clinical background, Thomas will add significantly to Cell Medica's Board capabilities at an important time in the Company's development.
...
Thomas helped build Amgen's haematology product sales in Europe and our lead Cytovir cell product is aimed at essentially the same clinical market. He is a seasoned board member with an excellent track record in helping early stage biotech companies to achieve significant growth and successful exits."
About Dr. Thomas Hecht
Thomas started his career in the department for bone marrow transplantation at the City of Hope Medical Center in Duarte, California and subsequently initiated the programme for bone marrow transplantation at the University of Freiburg in 1986. He then joined Amgen in 1989, as the company was setting up its European operations. Amgen's business grew significantly during this period and Thomas held various positions including Vice President - Marketing for Haematology and Oncology.
Since leaving Amgen, Thomas has worked as a biotech consultant and as a senior board member for several successful life sciences ventures. He was Chairman of ESBATech when Alcon, Inc acquired the privately held company in 2009. He continues as Chairman of Delenex Therapeutics AG, a spin-off of ESBATech. He was recently appointed as Chairman of Cytos Biotechnology AG and also chairs the board of Affimed Therapeutics AG and the advisory council of SuppreMol GmbH.
The Wellcome Trust will also ...
www.imperialinnovations.co.uk, 1 Oct 2013 [cached]
The Wellcome Trust will also become a shareholder in the business through elected conversion of a loan security into equity.

Cell Medica has also appointed Thomas Hecht as Chairman.
A former transplant physician, Thomas was vice president of marketing at Amgen Europe until 2002, and since then has been Chairman of a number of boards including Delenex and Cytos Biotechnology AG.
Other People with the name "Hecht":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304